Hims & Hers Health, Inc. HIMS is prioritizing a broader weight-loss offering and international expansion over immediate subscriber gains following its third-quarter <a href="https://bitcomme.com/ct-real-estate-investment-trust-ctrrf-q3-2026-earnings-call-highlights-strong-occupancy/” title=”CT Real Estate Investment Trust (CTRRF) (Q3 2026) Earnings Call Highlights: Strong Occupancy …”>2026 earnings call. Management expects the changes to position the platform for renewed customer acquisition in early 2027.
Revenues rose 49% year over year to $890.4 million, missing the Zacks Consensus Estimate of $893.4 million. The company reported earnings of $0.03 per share, which missed the consensus mark of $0.07. The discussion centered on investment timing, weakening gross margins and the economics of branded treatments.
Hims & Hers Health, Inc. Price, Consensus and EPS Surprise
Hims & Hers Health, Inc. price-consensus-eps-surprise-chart | Hims & Hers Health, Inc. Quote
HIMS Holds Back Marketing Ahead of Weight-Loss Expansion
Chief executive officer Andrew Dudum said that the company deliberately moderated U.S. weight-loss marketing while preparing new medications, pricing options and longer subscription plans. The decision reduced near-term customer acquisition.
Asked by Canaccord Genuity about subscriber trends, Okupe said that marketing would intensify around the first-quarter seasonal demand peak. He expects subscriber growth to recover after the expanded offering becomes available.
HIMS Broadens Drug Access Through Two Partners
Dudum highlighted plans to add Eli Lilly’s Zepbound and Foundayo alongside Novo Nordisk’s Wegovy products, with CagriSema planned once available. Multi-month subscriptions will offer additional pricing flexibility.
A Needham analyst questioned whether the marketing pullback reflected weaker returns. Dudum emphasized product assortment and subscription improvements rather than identifying deteriorating demand as the reason.
Okupe added that the company has previously seen broader selection support acquisition and retention. He expects acquisition benefits beginning in the first quarter, with retention benefits developing through 2027.
HIMS Cuts Profit Outlook Despite International Growth
Okupe narrowed full-year revenue guidance to $3.13 billion-$3.15 billion but lowered adjusted EBITDA guidance to $257 million-$277 million, reflecting planned international pricing and marketing investments and revenue deferrals.
Fourth-quarter guidance calls for revenues of $875 million-$895 million and adjusted EBITDA of $70 million-$90 million. Management also expects at least $20 million of full-year revenue and adjusted EBITDA pressure from membership deferrals.
